221 related articles for article (PubMed ID: 34833371)
21. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.
Ampuero J; Del Campo JA; Rojas L; García-Lozano JR; Solá R; Andrade R; Pons JA; Navarro JM; Calleja JL; Buti M; González-Escribano MF; Forns X; Diago M; García-Samaniego J; Romero-Gómez M
Ann Hepatol; 2014; 13(4):356-63. PubMed ID: 24927606
[TBL] [Abstract][Full Text] [Related]
22. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
Zampino R; Coppola N; Cirillo G; Boemio A; Pisaturo M; Marrone A; Macera M; Sagnelli E; Perrone L; Adinolfi LE; Miraglia del Giudice E
J Viral Hepat; 2013 Aug; 20(8):517-23. PubMed ID: 23808989
[TBL] [Abstract][Full Text] [Related]
23. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
24. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
[TBL] [Abstract][Full Text] [Related]
25. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection.
Ali M; Yopp A; Gopal P; Beg MS; Zhu H; Lee W; Singal AG
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):295-300. PubMed ID: 26305067
[TBL] [Abstract][Full Text] [Related]
26. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension.
Mandorfer M; Scheiner B; Stättermayer AF; Schwabl P; Paternostro R; Bauer D; Schaefer B; Zoller H; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferenci P; Ferlitsch A
Aliment Pharmacol Ther; 2018 Aug; 48(4):451-459. PubMed ID: 29956823
[TBL] [Abstract][Full Text] [Related]
27. Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients.
Gavril OI; Arhire LI; Gavril RS; Zota MI; Gherasim A; Nita O; Drugescu A; Oprescu AC; Esanu IM; Mitu F; Graur M; Mihalache L
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833467
[No Abstract] [Full Text] [Related]
28. Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.
Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Cirillo G; Grandone A; Salpietro S; Minichini C; Del Giudice EM; Lazzarin A; Sagnelli E; Coppola N
Clin Microbiol Infect; 2016 Apr; 22(4):372-378. PubMed ID: 26806136
[TBL] [Abstract][Full Text] [Related]
29. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
Valenti L; Maggioni P; Piperno A; Rametta R; Pelucchi S; Mariani R; Dongiovanni P; Fracanzani AL; Fargion S
World J Gastroenterol; 2012 Jun; 18(22):2813-20. PubMed ID: 22719190
[TBL] [Abstract][Full Text] [Related]
30. PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease.
Tortora R; Rispo A; Alisi A; Imperatore N; Crudele A; Ferretti F; Nobili V; Miele L; Gerbino N; Caporaso N; Morisco F
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30189691
[TBL] [Abstract][Full Text] [Related]
31. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Stättermayer AF; Rutter K; Beinhardt S; Wrba F; Scherzer TM; Strasser M; Hofer H; Steindl-Munda P; Trauner M; Ferenci P
Liver Int; 2014 Mar; 34(3):388-95. PubMed ID: 23870067
[TBL] [Abstract][Full Text] [Related]
32. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
[TBL] [Abstract][Full Text] [Related]
33. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.
Stättermayer AF; Rutter K; Beinhardt S; Scherzer TM; Stadlmayr A; Hofer H; Wrba F; Steindl-Munda P; Krebs M; Datz C; Trauner M; Ferenci P
J Hepatol; 2012 Sep; 57(3):492-8. PubMed ID: 22634340
[TBL] [Abstract][Full Text] [Related]
34. Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.
De Nicola S; Dongiovanni P; Aghemo A; Cheroni C; D'Ambrosio R; Pedrazzini M; Marabita F; Donnici L; Maggioni M; Fargion S; Colombo M; De Francesco R; Valenti L
PLoS One; 2014; 9(8):e106022. PubMed ID: 25171251
[TBL] [Abstract][Full Text] [Related]
35. The Influence of Metabolic Factors in Patients with Chronic Viral Hepatitis C Who Received Oral Antiviral Treatment.
Gavril OI; Gavril RS; Mitu F; Gavrilescu O; Popa IV; Tatarciuc D; Drugescu A; Oprescu AC; Gherasim A; Mihalache L; Esanu IM
Metabolites; 2023 Apr; 13(4):. PubMed ID: 37110229
[TBL] [Abstract][Full Text] [Related]
36. Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor.
Moritou Y; Ikeda F; Iwasaki Y; Baba N; Takaguchi K; Senoh T; Nagano T; Takeuchi Y; Yasunaka T; Ohnishi H; Miyake Y; Takaki A; Nouso K; Yamamoto K
Acta Med Okayama; 2014; 68(1):17-22. PubMed ID: 24553484
[TBL] [Abstract][Full Text] [Related]
37. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
38. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study.
Mueller JL; King LY; Johnson KB; Gao T; Nephew LD; Kothari D; Simpson MA; Zheng H; Wei L; Corey KE; Misdraji J; Lee JH; Lin MV; Gogela NA; Fuchs BC; Tanabe KK; Gordon FD; Curry MP; Chung RT
Clin Transplant; 2016 Apr; 30(4):452-60. PubMed ID: 26854475
[TBL] [Abstract][Full Text] [Related]
39. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
Miki D; Akita T; Kurisu A; Kawaoka T; Nakajima T; Hige S; Karino Y; Toyoda H; Kumada T; Tsuge M; Hiramatsu A; Imamura M; Aikata H; Hayes CN; Honda K; Seike M; Akuta N; Kobayashi M; Kumada H; Tanaka J; Chayama K
J Gastroenterol; 2020 Dec; 55(12):1162-1170. PubMed ID: 33057914
[TBL] [Abstract][Full Text] [Related]
40. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A; Petta S; Lombardi R; Di Marco V; Calvaruso V; Bertelli C; Pisano G; Fatta E; Sigon G; Iuculano F; Crapanzano L; Gibilaro G; Francione P; Craxì A; Fargion S; Fracanzani AL
Dig Liver Dis; 2021 Oct; 53(10):1301-1307. PubMed ID: 33214063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
